Detalhe da pesquisa
1.
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy.
J Pathol
; 263(2): 190-202, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38525811
2.
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study.
Gynecol Oncol
; 186: 17-25, 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554625
3.
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Gynecol Oncol
; 177: 20-31, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37625235
4.
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Gut
; 71(7): 1277-1288, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34433583
5.
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Lancet
; 396(10257): 1090-1100, 2020 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966830
6.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 379(22): 2108-2121, 2018 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30345906
7.
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(1): 44-59, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31786121
8.
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Gynecol Oncol
; 154(2): 314-322, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31204078
9.
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
J Neurooncol
; 140(2): 317-328, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30073642
10.
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection.
J Immunol
; 196(7): 2933-8, 2016 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26903482
11.
Basal NF-κB controls IL-7 responsiveness of quiescent naïve T cells.
Proc Natl Acad Sci U S A
; 111(20): 7397-402, 2014 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24799710
12.
T cell receptor/CARMA1/NF-κB signaling controls T-helper (Th) 17 differentiation.
Proc Natl Acad Sci U S A
; 109(45): 18529-34, 2012 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23091043
13.
High TCR stimuli prevent induced regulatory T cell differentiation in a NF-κB-dependent manner.
J Immunol
; 186(8): 4609-17, 2011 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21411734
14.
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
Clin Cancer Res
; 29(9): 1698-1707, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36595569
15.
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy.
Cell Rep Med
; 4(1): 100878, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36599350
16.
PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.
JCO Precis Oncol
; 6: e2100531, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772050
17.
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
Nat Commun
; 13(1): 7495, 2022 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36470901
18.
CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells.
J Immunol
; 182(11): 6736-43, 2009 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19454668
19.
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Appl Immunohistochem Mol Morphol
; 29(4): 258-264, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33030848
20.
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Clin Breast Cancer
; 21(6): 539-551, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34154926